Use of symptom-focused oncological cancer therapies in hospices: a retrospective analysis

Ulrich Kaiser(University of Applied Sciences Landshut), Florian Kaiser(University of Applied Sciences Landshut), Ana Hoffmann(University of Applied Sciences Landshut), Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Fabian Kück(Universitätsmedizin Göttingen), Nicolae-Catalin Mechie(Universitätsmedizin Göttingen)
BMC Palliative Care
September 12, 2020
10.1186/s12904-020-00648-4
Cited by 6

Related Papers

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
|The Lancet Oncology|2016|417
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
|Annals of Oncology|2006|280